Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Seattle Genetics acquires Cascadian

by Lisa M. Jarvis
February 5, 2018 | A version of this story appeared in Volume 96, Issue 6

Antibody-drug-conjugate-focused Seattle Genetics is shelling out roughly $614 million in cash to acquire Cascadian Therapeutics, a Seattle-based biotech focused on oncology. The centerpiece of the deal is tucatinib, a HER2 receptor inhibitor currently in Phase II trials as a treatment for people with HER2+ metastatic breast cancer. While two approved drugs, the antibody Herceptin and the antibody-drug conjugate Kadcyla, also target the HER2 receptor, tucatinib is an orally available small molecule, licensed to Cascadian from Array BioPharma.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.